









What Would Dr. James Parkinson Think Today?
II. Neuroimaging in Parkinson’s Disease
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Dr. James Parkinson would be impressed and grati-
fied by the progress made through the application of
neuroimaging methods in Parkinson disease (PD). Par-
kinson was considerably more than an astute and
articulate clinician. Parkinson epitomizes the produc-
tive scientists (a term coined by the English polymath
William Whewell in 1833) of his time. The great
majority of his scientific contemporaries were essen-
tially amateurs, either wealthy men such as the great
naturalist Joseph Banks, or middling class professio-
nals, often physicians or clergy, engaged in occupa-
tions that provided enough income and leisure time to
pursue intellectual interests. In the expanding public
sphere of Enlightenment Europe, physicians such as
Parkinson, Edward Jenner, and John Hunter were
active participants in broad networks of correspon-
dence, social clubs, and learned societies focused on
improving human knowledge. In addition to his signif-
icant contributions to medicine, Parkinson was a pio-
neering paleontologist and one of the founders of
British geoscience.
Parkinson’s famous essay demonstrates his under-
standing of the limitations of clinical observation and
the need for more definitive methods: “it is acknowl-
edged, that mere conjecture takes the place of experi-
ment; and, that analogy is the substitute for
anatomical explanation, the only sure foundation for
pathological knowledge.”1 In his time, “anatomical
explanation” was largely limited to the visual observa-
tion of gross pathologies. Parkinson used the best
available knowledge of his time to speculate about the
sites of pathology in PD: “A diseased state of the
medulla spinalis, in that part which is contained in the
canal, formed by the superior cervical vertebrae, and
extending, as the disease proceeds, to the medulla
oblongata.” Parkinson inferred correctly that the dis-
tinctive features of PD were different from those
resulting from peripheral nervous system pathologies.
His observations of initial limb, particularly arm,
involvement undoubtedly directed his attention to the
cervical spinal cord. His description of bulbar dysfunc-
tion in more advanced PD prompted his suggestion of
the progression of pathology to the medulla, a concept
that anticipates modern models of spreading CNS
pathology in PD.
Parkinson practiced when clinico-pathologic corre-
lation methods were pioneered by his contemporar-
ies John Hunter and Marie Francois Xavier Bichat.
In a recurring theme of the history of medicine,
technological improvements expanded the power of
clinico-pathologic correlation. In the 19th century,
improvements in microscope technology and the
development of histologic methods completely trans-
formed understanding of disease. Imaging technolo-
gies have had an analogous impact in our time.
Several papers in this issue of Movement Disorders
illustrate the power of contemporary imaging meth-
ods. Strafella and colleagues2 nicely review the
impact of molecular (positron emission tomography)
imaging on PD research. In a remarkable extension
of the clinico-pathologic correlation method, molec-
ular imaging methods allow in vivo identification of
key brain changes underlying specific features of PD.
Neuroimaging methods allow other forms of impor-
tant investigations in PD, such as expanding clinical
pharmacology and development of accurate bio-
markers. Politis and colleagues3 describe an interest-
ing study in which molecular imaging was used to
probe a key pharmacokinetic variable, striatal
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extracellular dopamine levels, during intestinal L-
dopa infusions. Langley and colleagues4 describe a
novel MRI analysis approach to measure a possible
marker of dopaminergic neuron degeneration, sub-
stantia nigra pars compacta iron deposition.
In addition to identifying crucial sites of pathology
in PD in vivo, modern imaging methods directly
address other important issues raised by Parkinson.
Parkinson was acutely aware of the need to differen-
tiate PD from other diseases. Although the discovery
of PD mimics such as progressive supranuclear pal-
sy, multiple system atrophy, and corticobasal syn-
drome lay decades in the future, Parkinson devoted
chapter III of An Essay on the Shaking Palsy
(“Shaking Palsy Distinguished From Other Diseases
With Which It May Be Confounded”) to clearly
establishing the distinctive features of PD. Parkin-
son’s discussion in this chapter demonstrates his
awareness that the accurate identification of disease
is necessary to understand pathogenetic mechanisms.
Parkinson was also clearly aware of the importance
of studying early phases of disease pathogenesis and
pathophysiology:
It seldom happens that the agitation extends
beyond the arms within the first two years; which
period, therefore, if we were disposed to divide the
disease into stages, might be said to comprise
the first stage. In this period, it is very probable,
that remedial means might be employed with
success.
Parkinson would probably be impressed with the
ability of imaging methods to interrogate early brain
changes in PD, which he would recognize as crucial to
developing disease-modifying therapies.
What Would Dr. Parkinson
Think Today?
Although Parkinson would be impressed by results
of neuroimaging studies of PD, and perhaps startled
by the power of these methods, the underlying intel-
lectual principles would be familiar. Parkinson was a
typical figure of the Enlightenment, and his achieve-
ments illustrate one of the great themes of the Enlight-
enment, the concept of useful knowledge. Inspired by
the success of Newtonian physics, Enlightenment intel-
lectuals believed that the underlying structure of the
universe was discoverable through the exercise of
human reason and that this knowledge could be used
for the benefit of humanity.5-7 In Parkinson’s time,
these were novel and contested ideas. Parkinson would
probably regard our present, albeit incomplete, under-
standing of PD as vindication of his ideals.
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